Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice.

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Abstract Text:

Hironori Yuyama,Akiko Koakutsu,Noriko Fujiyasu,Akira Fujimori,Shuichi Sato,Kumiko Shibasaki,Shohei Tanaka,Katsumi Sudoh,Masao Sasamata,Keiji Miyata,

In some diseases in which endothelin-1 (ET-1) production increases (e.g. prostate cancer), ET-1 is considered to be involved in the generation of pain. In the present study, we investigated the effects of a selective endothelin-A receptor antagonist, YM598, on the nociception potentiated by ET-1 in formalin-induced and cancer inoculation-induced pain models in mice. The formalin-induced pain model was prepared by intraplantar injection of 0.7% formalin into the hind paws of ICR mice, and the cancer pain model was prepared by inoculation of the human prostate cancer cell line PPC-1 into the hind paws of severe combined immunodeficiency mice. Formalin caused a biphasic pain response and paw edema in the mouse hind paw. ET-1 (10 pmol/paw) potentiated these responses, and single oral administration of YM598 (0.3-3 mg/kg) significantly inhibited this ET-1-induced potentiation of nociception and paw edema. ET-1 (10 pmol/paw) also potentiated the pain response in prostate cancer-inoculated mice. Both YM598 and atrasentan (0.3-3 mg/kg) significantly inhibited the ET-1-induced potentiation of nociception. These results suggest that selective endothelin-A receptor antagonists relieve pain in patients with various diseases in which ET-1 production increases (e.g. prostate cancer).

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Publishing Authors By Initials

H Yuyama,A Koakutsu,N Fujiyasu,A Fujimori,S Sato,K Shibasaki,S Tanaka,K Sudoh,M Sasamata,K Miyata,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of cardiovascular pharmacology

VOLUME: 44 Suppl 1

Page Numbers: S479-82

Journal Abbreviation: J. Cardiovasc. Pharmacol.

ISSN: 1533-4023

DAY: 19

MONTH: Nov

YEAR: 2004

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7902492

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice.

AFFILIATION: Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd, Tsukuba-shi, Ibaraki, Japan. yuyama@yamanouchi.co.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Cardiovasc Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice Related Publications

• A large deletion of the PROS1 gene in a deep vein thrombosis patient with protein S deficiency.
• A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.
• A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
• Analysis of the p450 aromatase gene expression in the Xenopus brain and gonad.
• Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model.
• Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others.
• Cytoskeletal "jellyfish" structure of Mycoplasma mobile.
• Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
• Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells.
• Distinct properties of corticothalamic and primary sensory synapses to thalamic neurons.
• Editorial.
• Establishment of a sandwich ELISA for human megsin, a kidney-specific serine protease inhibitor.
• Identification of a cross-linked peptide of a covalent complex between adrenodoxin reductase and adrenodoxin.
• Insecticide susceptibility of surviving Cotesia plutellae (Hym: Braconidae) and Diaeretiella rapae (M'Intosh) (Hym: Aphidiidae) as affected by sublethal insecticide dosages on host insects.
• Interleukin-11 acts synergistically with bone morphogenetic protein-2 to accelerate bone formation in a rat ectopic model.
• Interleukin-11 induces osteoblast differentiation and acts synergistically with bone morphogenetic protein-2 in C3H10T1/2 cells.
• Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods.
• New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation.
• Outbreak of CTX-M-3-type extended-spectrum beta-lactamase-producing Enterobacter cloacae in a pediatric ward.
• Preliminary X-ray studies on Serratia protease.
• Protein tyrosine kinase 2beta as a candidate gene for hypertension.
• Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
• Studies on denitrification. XIV. The electron donating system in the reduction of nitric oxide and nitrate.
• Survey of the morphogenetic dynamics of the ventricular surface of the developing mouse neocortex.
• Synergism between interleukin-11 and bone morphogenetic protein-2 in the healing of segmental bone defects in a rabbit model.
• The NH2-terminal structures of human and rat liver microsomal NADH-cytochrome b5 reductases.
• Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.
• [A case of pancreatic endocrine tumor associated with Cushing's syndrome]
• [Atrioventricular dissociation]
• [Molecular mechanism of Mycoplasma gliding; a unique biomotility]